Sweden · Delayed Price · Currency is SEK BioArctic AB Statistics
Total Valuation
BioArctic AB has a market cap or net worth of SEK 27.52 billion. The enterprise value is 25.62 billion.
| Market Cap | 27.52B |
| Enterprise Value | 25.62B |
Important Dates
The next confirmed earnings date is Wednesday, November 25, 2026.
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
BioArctic AB has 88.72 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Current Share Class | 74.32M |
| Shares Outstanding | 88.72M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | -0.16% |
| Owned by Insiders (%) | 31.99% |
| Owned by Institutions (%) | 43.90% |
| Float | 54.58M |
Valuation Ratios
The trailing PE ratio is 261.92 and the forward PE ratio is 50.11.
| PE Ratio | 261.92 |
| Forward PE | 50.11 |
| PS Ratio | 28.07 |
| PB Ratio | 13.96 |
| P/TBV Ratio | 13.96 |
| P/FCF Ratio | 120.41 |
| P/OCF Ratio | 115.35 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 123.83, with an EV/FCF ratio of 112.28.
| EV / Earnings | 248.70 |
| EV / Sales | 26.18 |
| EV / EBITDA | 123.83 |
| EV / EBIT | 133.41 |
| EV / FCF | 112.28 |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.99 |
| Quick Ratio | 2.97 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.43 |
| Debt / FCF | 0.39 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 5.21% and return on invested capital (ROIC) is 52.02%.
| Return on Equity (ROE) | 5.21% |
| Return on Assets (ROA) | 4.78% |
| Return on Invested Capital (ROIC) | 52.02% |
| Return on Capital Employed (ROCE) | 9.16% |
| Weighted Average Cost of Capital (WACC) | 0.78% |
| Revenue Per Employee | 6.68M |
| Profits Per Employee | 703,487 |
| Employee Count | 150 |
| Asset Turnover | 0.39 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioArctic AB has paid 143.11 million in taxes.
| Income Tax | 143.11M |
| Effective Tax Rate | 57.56% |
Stock Price Statistics
The stock price has increased by +7.31% in the last 52 weeks. The beta is -0.63, so BioArctic AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.63 |
| 52-Week Price Change | +7.31% |
| 50-Day Moving Average | 313.59 |
| 200-Day Moving Average | 316.97 |
| Relative Strength Index (RSI) | 55.86 |
| Average Volume (20 Days) | 105,110 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioArctic AB had revenue of SEK 1.00 billion and earned 105.52 million in profits. Earnings per share was 1.18.
| Revenue | 1.00B |
| Gross Profit | 933.97M |
| Operating Income | 196.72M |
| Pretax Income | 248.63M |
| Net Income | 105.52M |
| EBITDA | n/a |
| EBIT | 196.72M |
| Earnings Per Share (EPS) | 1.18 |
Balance Sheet
The company has 1.99 billion in cash and 90.61 million in debt, with a net cash position of 1.90 billion or 21.41 per share.
| Cash & Cash Equivalents | 1.99B |
| Total Debt | 90.61M |
| Net Cash | 1.90B |
| Net Cash Per Share | 21.41 |
| Equity (Book Value) | 2.02B |
| Book Value Per Share | 22.72 |
| Working Capital | 2.01B |
Cash Flow
In the last 12 months, operating cash flow was 243.98 million and capital expenditures -10.24 million, giving a free cash flow of 233.73 million.
| Operating Cash Flow | 243.98M |
| Capital Expenditures | -10.24M |
| Depreciation & Amortization | 15.24M |
| Net Borrowing | 890,000 |
| Free Cash Flow | 233.73M |
| FCF Per Share | 2.63 |
Margins
Gross margin is 93.17%, with operating and profit margins of 19.62% and 10.53%.
| Gross Margin | 93.17% |
| Operating Margin | 19.62% |
| Pretax Margin | 24.80% |
| Profit Margin | 10.53% |
| EBITDA Margin | n/a |
| EBIT Margin | 19.62% |
| FCF Margin | 23.32% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 0.64%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 0.64% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 168.87% |
| FCF Payout Ratio | 75.92% |
| Buyback Yield | -0.12% |
| Shareholder Yield | 0.51% |
| Earnings Yield | 0.38% |
| FCF Yield | 0.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for BioArctic AB is 314.00, which is 1.23% higher than the current price. The consensus rating is "Buy".
| Price Target | 314.00 |
| Price Target Difference | 1.23% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 11.01% |
| EPS Growth Forecast (3Y) | 9.96% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |